Detalhe da pesquisa
1.
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Br J Cancer
; 129(12): 2003-2013, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731022
2.
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Invest New Drugs
; 41(1): 115-121, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633784
3.
The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer.
Oncology
; 101(11): 695-704, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37494886
4.
The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.
Oncology
; 101(1): 69-76, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103811
5.
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Oncology
; 101(11): 685-694, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166346
6.
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease.
Invest New Drugs
; 40(1): 182-189, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415485
7.
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
Invest New Drugs
; 40(2): 430-437, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807331
8.
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
BMC Cancer
; 22(1): 1314, 2022 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36522630
9.
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.
Proc Natl Acad Sci U S A
; 116(20): 10025-10030, 2019 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31043566
10.
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Cancer Sci
; 112(9): 3784-3795, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34145930
11.
Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress.
Oncologist
; 26(12): e2265-e2273, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34510654
12.
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Invest New Drugs
; 39(2): 530-536, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159674
13.
Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study.
Palliat Med
; 35(5): 943-951, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761790
14.
Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.
Cancer Sci
; 111(10): 3793-3801, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32687646
15.
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
Invest New Drugs
; 38(6): 1906-1914, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415486
16.
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Invest New Drugs
; 38(3): 885-893, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32157598
17.
Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
BMC Cancer
; 19(1): 163, 2019 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30808322
18.
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Br J Cancer
; 129(12): 2034, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37923915
19.
Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.
Oncologist
; 23(10): 1218-1229, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30120158
20.
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Oncology
; 94(4): 207-214, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29393275